Here’s a paraphrased version of the article, structured in HTML format:
<div>
<h2>Top Dividend Stocks to Consider This September</h2>
<p>Abbott Laboratories has a strong reputation for consistency and dividend growth.</p>
<p>AbbVie presents attractive options for income, growth, and value investors.</p>
<p>Eli Lilly offers a rapidly increasing dividend alongside excellent growth opportunities.</p>
<p>Three contributors from Motley Fool have identified dividend stocks worth buying this September, categorizing them as no-brainers. The highlighted choices are <strong>Abbott Laboratories</strong> (NYSE: ABT), <strong>AbbVie</strong> (NYSE: ABBV), and <strong>Eli Lilly</strong> (NYSE: LLY).</p>
<h3>Abbott Laboratories: A Reliable Long-term Investment</h3>
<p><strong>David Jagielski</strong> notes that Abbott Laboratories stands out as a top dividend stock for long-term investors. While it may not have the highest yield, its historical stability makes it a sensible choice. Currently, Abbott pays a 1.8% dividend, exceeding the S&P 500's average of 1.2%. Over the years, Abbott has consistently increased its dividends and most recently raised its payout by 7.3%, marking 53 years of consecutive increases. Its dividends have increased by over 60% since 2020.</p>
<h3>AbbVie: A Strong Performer for Income and Growth</h3>
<p><strong>Keith Speights</strong> points out that AbbVie, which was spun off from Abbott Laboratories in 2013, has inherited a history of dividend increases, boasting a current yield near 3%. Despite the challenges stemming from the patent expiration of its top-selling drug, Humira, AbbVie has shown resilience, outperforming the S&P 500 in recent years. The company anticipates continued earnings growth, propelled by strong sales of Humira's successors, Skyrizi and Rinvoq, along with other successful drugs in its portfolio.</p>
<h3>Eli Lilly: Innovating Beyond Weight Loss</h3>
<p><strong>Prosper Junior Bakiny</strong> highlights Eli Lilly's prominence in the pharmaceutical sector, particularly in the weight loss market with drugs like Mounjaro and Zepbound. The company is not limited to this niche—its portfolio boasts successful cancer treatments like Verzenio and potentially lucrative recent additions such as Ebglyss for eczema. With a promising pipeline for cardiovascular treatments, Eli Lilly showcases a robust growth trajectory alongside a history of increasing dividends, currently yielding 0.8%.</p>
<h3>Conclusion: Strong Options for Investors</h3>
<p>Before considering an investment in AbbVie, be aware that the <em>Motley Fool Stock Advisor</em> team has pinpointed other stocks they believe may be more promising. This list includes stocks that could yield significant returns over time. Investing based on proven historical performance, as showcased by Netflix and Nvidia, demonstrates the potential for high returns with the right choices.</p>
</div>This version maintains the core information while paraphrasing the content effectively, formatted into distinct sections for clarity.
